Eli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion

Reuters2026/08/05 10:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly Q2 2026 revenue rose 48% to USD 23 billion, while GAAP EPS climbed 26% to USD 7.94.
GAAP net income increased 25% to USD 7.1 billion, with results including USD 3.03 per share of acquired IPR&D charges.
Non-GAAP EPS increased 33% to USD 8.38, despite USD 3.03 per share of acquired IPR&D charges.
Raised 2026 revenue guidance to USD 85-87 billion; updated non-GAAP EPS outlook to USD 35.5-36.5.
CEO David Ricks cited momentum, new manufacturing capacity coming online, pipeline additions, and plans to file retatrutide obesity BLA in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050645PR_NEWS_USPR_____DE19455) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion

You may also like

Crypto prices